Upadacitinib is now approved in European Union to treat active polyarticular juvenile idiopathic arthritis (pJIA) ages > 2yrs for those not responding to 1+ DMARDs. In the USA, UPA is approved for pJIA & juvenile PsA https://t.co/Vhx717rw5T https://t.co/hObov1Umgb

BMJ reports TriNetX EHR study showing GLP-1 RA use in knee OA pts was assoc w/ significantly lower cumulative TKA incidence (p<0.001).  1 year any GLP-1 RA (HR 0.90) or 3 yrs exposure (HR 0.72) signif lowered TKA 8 yrs later https://t.co/RGQJJHgLFv https://t.co/Ko7VI3ZAC0

Amgen announced topline results from the Phase 3 OASIZ 301 study showing the efficacy of dazodalibep in Sjögren's dz, w/ signif ESSDAI improvements at wek 48. DAZO is a CD40L antagonist fusion protein https://t.co/5QPBdZivxC https://t.co/tJvYo6TrWO

Metanalysis of Metabolic syndrome (MetS) in #SLE (65 articles, 11K pts). MetS prevalence 27% (higher in males (36 vs 27%). HCQ assoc w/ signif less MetS (OR 0.66), but more w/ CTX (1.39), AZA (1.25), MMF (1.13), but not steroids or MTX. MetS pts were older, obese, w/ high Chol & https://t.co/ZbVwGTy0rG

Cluster analysis of Spanish RELES #SLE SLE cohort reveals 3 groups. C1 (n 168) was younger, w/ lupus nephritis, low C3, intensive Rx, high infx & damage. C2 (175) w/ cytopenias, serositis, APL & dsDNA(+). C3 (452) mild skin-Jts, less serologic activity & complications https://t.co/N0XLUaegWc

J&J announced topline results of Phase 4 STAR study where guselkumab (Tremfya) improved in axial Sxs & MRI outcomes in 411 biologic-naïve axial PsA pts, STAR is a 24 wk DBPCT of GUS (IL-23 inhib) in DMARD unresponsive pts. Endpoint was BASDAI @ wk24. https://t.co/LkqwV0zRmn https://t.co/gZuuQ4jcEf

Remission — believe it or not. What’s happening in rheumatology this week? Dr. Jack Cush breaks down the latest news and journal reports on RheumNow: 10-year T2T data: 82% in remission Residual steroids don’t preserve remission Biologics linked to lower PsA risk GLP-1s + knee OA https://t.co/2Zf9g1Wehg

DERM on RheumNow PODCAST (September 2026) The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors. https://t.co/QYX9G5UFg5

The GLP-1 Opportunity Cost in Rheumatology There is no doubt it is an incredibly exciting time to be tackling obesity-related diseases, like many rheumatic diseases appear to be, to some extent. https://t.co/49EscdPOTG https://t.co/c0kSgOXZy7

Supervised Physiotherapy Wins after ACL Repair The Annals of Internal Medicine has shown that chronic knee symptoms following anterior cruciate ligament reconstruction (ACLR) surgery is significantly lessened by a program of physiotherapist-supervised exercise therapy with https://t.co/8HWmkmIexr

The weight is off, the DMARDs are off - now what? Sometimes it’s only when we have effective solutions that we have to think about what to do next. And when that happens, remember why we do things in the first place. In an era when weight loss is happening on scale, now we need https://t.co/MTjU5YRS5q

Observational study of 228 #PsA pts Rx biologics, either early (<2yrs; mean 6 mos) vs later (mean 3.6 yrs). Groups were balanced in all parameters; after 6 mos no diff in DAPSA50 or PASI75 response. Biologics work regardless of when started. https://t.co/ZCDR8l2CsI https://t.co/PHgtgZu12G

Treatment for Obesity and Inflammation, but at what Cost? https://t.co/v87FxQqrAv https://t.co/Oonrexyp0F

Obesity & Biologic Treatment Response Prepared for "The Obesity Imperative" campaign. https://t.co/72TFW6BWgG https://t.co/XWFWoH2D33